Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease

Although immunotherapies against the amyloid-β (Aβ) peptide tried so date failed to prove sufficient clinical benefit, Aβ still remains the main target in Alzheimer’s disease (AD). This article aims to show the rationale of a new therapeutic strategy: clearing Aβ from the CSF continuously (the “CSF-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Aging Neurosci
Auteurs principaux: Menendez-Gonzalez, Manuel, Padilla-Zambrano, Huber S., Alvarez, Gabriel, Capetillo-Zarate, Estibaliz, Tomas-Zapico, Cristina, Costa, Agustin
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2018
Sujets:
Neuroscience
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5911461/
https://ncbi.nlm.nih.gov/pubmed/29713273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnagi.2018.00100
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires